Avidity Biosciences Inc., a biopharmaceutical company focused on RNA therapeutics, announced new inducement grants under its 2022 Employment Inducement Incentive Award Plan. On May 20, 2025, the company's Human Capital Management Committee granted non-qualified stock option awards for 71,000 shares and 35,000 restricted stock units (RSUs) to sixteen new non-executive employees. These inducement awards are part of the company's efforts to attract new talent and are issued in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $31.64 per share, matching the closing price of Avidity's stock on the Nasdaq Global Market on the grant date. The options and RSUs will vest over four years, contingent upon the employees' continued employment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。